Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced an extension of its partnership with Unilever to enter a new phase aimed at initiating in-vivo efficacy testing of Optimer binders as active ingredients in deodorants.
Initiated in 2022, the partnership between Aptamer and Unilever aims to develop Optimer binders as part of novel deodorant products. The current market value for deodorants is in excess of $21 billion per annum and growing at 4.5% (CAGR for the next 5 years). Unilever is the leader in the deodorant market, with over 30% market share – an increase of over 20% compared to its nearest competitor. The use of active ingredients such as Optimer binders within deodorant products is highly novel within the market and holds the potential for enhanced efficacy for consumer products.
